OBJECTIVE: Endogenous cardiotonic steroids, including marinobufagenin (MBG), stimulate vascular synthesis of collagen. Because mineralocorticoid antagonists competitively antagonize effect of cardiotonic steroids on the Na/K-ATPase, we hypothesized that spironolactone would reverse the profibrotic effects of MBG. METHODS: Experiment 1: Explants of thoracic aortae and aortic vascular smooth muscle cells from Wistar rats were cultured for 24 h in the presence of vehicle or MBG (100 nmol/l) with or without canrenone (10 μmol/l), an active metabolite of spironolactone. Experiment 2: In 16 patients (56 ± 2 years) with resistant hypertension on a combined (lisinopril/amlodipine/hydrochlorothiazide) therapy, we determined arterial pressure, pulse wave velocity, plasma MBG, and erythrocyte Na/K-ATPase before and 6 months after addition of placebo (n = 8) or spironolactone (50 mg/day; n = 8) to the therapy. RESULTS: In rat aortic explants and in vascular smooth muscle cells, pretreatment with MBG resulted in a two-fold rise in collagen-1, and a marked reduction in the sensitivity of the aortic rings to the vasorelaxant effect of sodium nitroprusside following endothelin-1-induced constriction (EC50 = 480 ± 67 vs. 23 ± 3 nmol/l in vehicle-treated rings; P < 0.01). Canrenone blocked effects of MBG on collagen synthesis and restored sensitivity of vascular rings to sodium nitroprusside (EC50 = 17 ± 1 nmol/l). Resistant hypertension patients exhibited elevated plasma MBG (0.42 ± 0.07 vs. 0.24 ± 0.03 nmol/l; P = 0.01) and reduced Na/K-ATPase activity (1.9 ± 0.15 vs. 2.8 ± 0.2 μmol Pi/ml per h, P < 0.01) vs. seven healthy individuals. Six-month administration of spironolactone, unlike placebo treatment, was associated with a decrease in pulse wave velocity and arterial pressure, and with restoration of Na/K-ATPase activity in the presence of unchanged MBG levels. CONCLUSION: MBG-induced vascular fibrosis is a likely target for spironolactone.
OBJECTIVE: Endogenous cardiotonic steroids, including marinobufagenin (MBG), stimulate vascular synthesis of collagen. Because mineralocorticoid antagonists competitively antagonize effect of cardiotonic steroids on the Na/K-ATPase, we hypothesized that spironolactone would reverse the profibrotic effects of MBG. METHODS: Experiment 1: Explants of thoracic aortae and aortic vascular smooth muscle cells from Wistar rats were cultured for 24 h in the presence of vehicle or MBG (100 nmol/l) with or without canrenone (10 μmol/l), an active metabolite of spironolactone. Experiment 2: In 16 patients (56 ± 2 years) with resistant hypertension on a combined (lisinopril/amlodipine/hydrochlorothiazide) therapy, we determined arterial pressure, pulse wave velocity, plasma MBG, and erythrocyte Na/K-ATPase before and 6 months after addition of placebo (n = 8) or spironolactone (50 mg/day; n = 8) to the therapy. RESULTS: In rat aortic explants and in vascular smooth muscle cells, pretreatment with MBG resulted in a two-fold rise in collagen-1, and a marked reduction in the sensitivity of the aortic rings to the vasorelaxant effect of sodium nitroprusside following endothelin-1-induced constriction (EC50 = 480 ± 67 vs. 23 ± 3 nmol/l in vehicle-treated rings; P < 0.01). Canrenone blocked effects of MBG on collagen synthesis and restored sensitivity of vascular rings to sodium nitroprusside (EC50 = 17 ± 1 nmol/l). Resistant hypertensionpatients exhibited elevated plasma MBG (0.42 ± 0.07 vs. 0.24 ± 0.03 nmol/l; P = 0.01) and reduced Na/K-ATPase activity (1.9 ± 0.15 vs. 2.8 ± 0.2 μmol Pi/ml per h, P < 0.01) vs. seven healthy individuals. Six-month administration of spironolactone, unlike placebo treatment, was associated with a decrease in pulse wave velocity and arterial pressure, and with restoration of Na/K-ATPase activity in the presence of unchanged MBG levels. CONCLUSION:MBG-induced vascular fibrosis is a likely target for spironolactone.
Authors: Doris M Tham; Baby Martin-McNulty; Yi-Xin Wang; Valdeci Da Cunha; Dennis W Wilson; Christian N Athanassious; Andrew F Powers; Mark E Sullivan; John C Rutledge Journal: Am J Physiol Regul Integr Comp Physiol Date: 2002-09-12 Impact factor: 3.619
Authors: Steven T Haller; David J Kennedy; Amjad Shidyak; George V Budny; Deepak Malhotra; Olga V Fedorova; Joseph I Shapiro; Alexei Y Bagrov Journal: Am J Hypertens Date: 2012-03-01 Impact factor: 2.689
Authors: Olga V Fedorova; Mark I Talan; Natalia I Agalakova; Edward G Lakatta; Alexei Y Bagrov Journal: Circulation Date: 2002-03-05 Impact factor: 29.690
Authors: Kristen L Jablonski; Olga V Fedorova; Matthew L Racine; Candace J Geolfos; Phillip E Gates; Michel Chonchol; Bradley S Fleenor; Edward G Lakatta; Alexei Y Bagrov; Douglas R Seals Journal: Clin J Am Soc Nephrol Date: 2013-08-08 Impact factor: 8.237
Authors: Igor V Emelyanov; Alexandra O Konradi; Edward G Lakatta; Olga V Fedorova; Alexei Y Bagrov Journal: Curr Top Membr Date: 2019-02-18 Impact factor: 3.049
Authors: Yulia N Grigorova; Ondrej Juhasz; Valentina Zernetkina; Kenneth W Fishbein; Edward G Lakatta; Olga V Fedorova; Alexei Y Bagrov Journal: Am J Hypertens Date: 2015-09-07 Impact factor: 2.689
Authors: Olga V Fedorova; Artem V Fadeev; Yulia N Grigorova; Courtney A Marshall; Valentina Zernetkina; Nikolai I Kolodkin; Natalia I Agalakova; Alexandra O Konradi; Edward G Lakatta; Alexei Y Bagrov Journal: J Cardiovasc Pharmacol Date: 2019-11 Impact factor: 3.105
Authors: Jennifer La; Eleanor B Reed; Svetlana Koltsova; Olga Akimova; Robert B Hamanaka; Gökhan M Mutlu; Sergei N Orlov; Nickolai O Dulin Journal: Am J Physiol Lung Cell Mol Physiol Date: 2016-02-05 Impact factor: 5.464
Authors: Michél Strauss; Wayne Smith; Wen Wei; Alexei Y Bagrov; Olga V Fedorova; Aletta E Schutte Journal: J Hypertens Date: 2018-12 Impact factor: 4.844